Retirement Systems of Alabama decreased its position in shares of Hologic Inc. (NASDAQ:HOLX) by 78.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 123,671 shares of the company’s stock after selling 440,848 shares during the period. Retirement Systems of Alabama’s holdings in Hologic were worth $4,279,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the stock. Cleararc Capital Inc. purchased a new stake in Hologic during the first quarter worth $213,000. QUANTRES ASSET MANAGEMENT Ltd purchased a new stake in Hologic during the second quarter worth $391,000. DNB Asset Management AS raised its stake in Hologic by 8.1% in the second quarter. DNB Asset Management AS now owns 13,405 shares of the company’s stock worth $464,000 after buying an additional 1,000 shares during the period. LS Investment Advisors LLC raised its stake in Hologic by 13.1% in the second quarter. LS Investment Advisors LLC now owns 13,453 shares of the company’s stock worth $465,000 after buying an additional 1,557 shares during the period. Finally, BlueMountain Capital Management LLC purchased a new stake in Hologic during the first quarter worth $464,000. Institutional investors own 94.51% of the company’s stock.
Hologic Inc. (NASDAQ:HOLX) traded up 0.34% during mid-day trading on Friday, reaching $38.45. 1,547,204 shares of the company’s stock were exchanged. The company’s 50-day moving average is $38.49 and its 200 day moving average is $36.36. Hologic Inc. has a one year low of $31.84 and a one year high of $41.66. The firm has a market capitalization of $10.67 billion, a P/E ratio of 42.39 and a beta of 1.00.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.03. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The business had revenue of $717.40 million for the quarter, compared to analysts’ expectations of $703.66 million. During the same quarter in the previous year, the business posted $0.43 earnings per share. The business’s revenue was up 3.4% compared to the same quarter last year. Equities analysts predict that Hologic Inc. will post $1.94 earnings per share for the current fiscal year.
A number of analysts recently weighed in on the stock. Evercore ISI reaffirmed a “buy” rating and set a $43.00 target price on shares of Hologic in a report on Saturday. Leerink Swann reaffirmed an “outperform” rating and set a $46.00 target price on shares of Hologic in a report on Monday, October 3rd. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Wednesday, September 28th. Barclays PLC raised shares of Hologic from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $42.00 to $44.00 in a report on Friday, September 23rd. Finally, Piper Jaffray Cos. set a $44.00 target price on shares of Hologic and gave the stock a “hold” rating in a report on Sunday, August 28th. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $42.76.
In other news, VP Karleen Marie Oberton sold 31,470 shares of the business’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $40.00, for a total transaction of $1,258,800.00. Following the completion of the sale, the vice president now directly owns 17,005 shares of the company’s stock, valued at $680,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nancy Leaming sold 8,179 shares of the business’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $37.00, for a total transaction of $302,623.00. Following the sale, the director now directly owns 67,140 shares of the company’s stock, valued at $2,484,180. The disclosure for this sale can be found here. Insiders own 0.84% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.